Clinical Trials - September 8, 2014
Bavarian Nordic accelerates Ebola vaccine development
Bavarian Nordic A/S will accelerate its collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), on the development of its Ebola vaccine programs. Bavarian Nordic and partners are planning to initiate the first trial of a promising combination vaccine regimen in humans in 2015. Bavarian […]
Acquisition - April 29, 2013
Multi-million dollar contract for Bavarian Nordic
Danish Bavarian Nordic receives contract valued up to USD 228 Million from the U.S. Government.
Biotech Business - February 27, 2013
Bavarian Nordic consolidates vaccine manufacturing in Denmark
The company will consolidate its manufacturing activities in Kvistgaard, Denmark with the aim of optimizing productivity and profitability. As part of this consolidation, the company will prepare the Kvistgaard facility for the future commercial production of its prostate cancer vaccine, PROSTVAC and also transfer its production of clinical trial material to the facility. Consequently, the […]
